Mereo BioPharma Group plc (MREO)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | — | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-19) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-10) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-12) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-13) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-26) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-13) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-15) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-27) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Changes In Equity | ||
| Notes | ||
| Accrued Expenses | ||
| Basis of Presentation and Summary of Significant Accounting Policies | ||
| Commitments and Contingencies | ||
| Convertible Loan Notes | ||
| Convertible Loan Notes and Equity Classified Warrants | — |
|
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Fair Value Measurements | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Intangible Assets | — |
|
| Leases | ||
| Loss Per Share | ||
| Nature of Business | ||
| Other Current Liabilities | ||
| Other Income/(expenses) , Net | — |
|
| Pay Vs Performance Disclosure | ||
| Prepaid Expenses and Other Current Assets | ||
| Property and Equipment , Net | ||
| Recent Accounting Pronouncements | ||
| Related Party Disclosures | ||
| Revenue and Cost of Revenue | ||
| Segment Information | ||
| Share Based Compensation | ||
| Shareholders' Equity | ||
| Subsequent Events | ||
| Warrant Liability | ||